RVCL stands for retinal vasculopathy with cerebral leukodystrophy. It is an inherited disorder whose symptoms initially begin at middle age and affect the eye and brain.
As an autosomal dominant disease, it affects both males and females equally. A person with RVCL has a 50-50 chance of passing it along to any of their children. If a son or daughter does not get the disease (i.e., inherit the gene), they and their offspring are safe.
Since RVCL is such a rare disease, it has also been referred to as cerebroretinal vasculopathy (CRV), hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS), and hereditary vascular retinopathy (HVR).
RVCL is a very rare genetic disease caused by a mutation in the TREX1 gene that lies on chromosome 3.
DNA consists of two strands, one strand inherited from each parent. Thus, RVCL individuals carry one normal gene on one strand and one mutated TREX1 gene on the other. This means that individuals with the TREX1 mutation have a 50% chance of passing it along to each offspring.
Exactly how TREX1 mutation causes damage to small blood vessels is unknown.
In its protein form, TREX1 is localized inside cells in a labyrinth of ‘sacks’ or membranes called the endoplasmic reticulum (ER). The ER is attached to the nucleus of each cell and serves important roles in manufacturing and releasing proteins needed by the body. In RVCL, TREX1 mutations occur in the last one-third to one-fourth of this rather small and very common protein. This type of TREX1 mutation results in a shortened, incomplete protein.
The tail of TREX1 is important for keeping it localized to its normal place in the ER compartment of cells. The loss of its tail causes it to mislocalize and spread throughout the cell. Because it loses its ability to stay in its proper location, we referred to this as “TREX on the loose.”
How this modified protein lacking its tail causes RVCL is unknown.
The symptoms RVCL patients develop indicate that when TREX1 mislocalizes it particularly affects the innermost cells that line blood vessels (called “endothelial cells”).
Part of the goal of the RVCL Research Center is to conduct basic research on TREX1 to better understand its biochemistry and functions and how that may relate to RVCL.
RVCL symptoms usually begin in middle age (35-50 years) with eye issues such as an increasing number of “floaters” and “blind spots.” It then may progress to the brain and other organs.
The main pathological process of RVCL is that small blood vessels prematurely “drop out,” that is, deteriorate and disappear. This leads to mini- strokes called “micro-infarcts” in tissues. Initially, the loss of blood supply particularly affects both the eye (retina) and the brain (white matter) since these organs have key functions sensitive to any type of disruption in blood flow.
Frequently, the continuing vessel “drop out” progressively leads to increasing vision loss and larger brain infarcts or tumor-like lesions, especially if mini-strokes are clustered.
Because RVCL is so rare, it is often misdiagnosed as “bad” multiple sclerosis, diabetic retinopathy, a brain tumor, or a vasculitis (blood vessel inflammation).
However, correct diagnosis of RVCL can be made by genetic testing that conclusively establishes if a patient has the disease.
We are focused on establishing and coordinating studies on the clinical course, pathology, and therapeutic interventions for affected, or symptomatic, RVCL patients.
There currently is no treatment for RVCL; however, there is a way to prevent transmission of the disease to the next generation. Please contact us if you’d like to know more about reproductive choices or clinical trials.
For additional information on RVCL, see our review on the website of the National Organization for Rare Diseases (NORD).
Feature photo: Small blood vessel damage in RVCL. On the left, interior blood vessel wall thickens restricting blood flow. On the right, collagen deposits in concentric circles inside vessel walls.